BioNTech co-founder Ugur Sahin said on Thursday the frontrunner Covid-19 vaccine his German firm is developing with Pfizer could be rolled out before the year is over in the United States or Europe.
BioNTech and Bristol will evenly split the costs of developing and commercializing BNT327, and will "work jointly to broaden and accelerate the development of this clinical candidate." The drug is ...
NEW YORK (Reuters) — The chief executive of Germany’s BioNTech SE said the biggest challenge facing it and partner Pfizer Inc now that their COVID-19 vaccine is authorized for use in the United States ...
JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (BNTX) (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech (NTGN), visited Israel to meet with ...
BioNTech said Thursday it has agreed to acquire smaller biotech CureVac in a $1.25 billion all-stock deal in a push to advance its cancer drug portfolio. CureVac stock soared 31% to $5.33 in premarket ...
The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values CureVac at around $1.25 billion. Once complete, CureVac will be wholly absorbed ...
LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results